Cellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies Apr 27, 2017
Cellectar Biosciences Receives Additional U.S. Patents for PDC Optical Agents in the Detection of Multiple Cancers Apr 25, 2017
UPDATED: Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Apr 21, 2017
Cellectar Biosciences Receives Japanese Patent for CLR 131 and CLR 125 for the Treatment of Cancer Stem Cells Apr 18, 2017
Cellectar Biosciences Strengthens Management Team with Appointment of John Friend, M.D. as Chief Medical Officer Apr 12, 2017
Cellectar Biosciences Adds Industry Veterans Douglas Swirsky and Frederick Driscoll to Its Board of Directors Apr 10, 2017
After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers Mar 30, 2017
Cellectar Biosciences Further Deepens Intellectual Property Portfolio with Patent Grant for PET Imaging PDC Mar 21, 2017
Cellectar Biosciences Reports 2016 Company Performance and Continued Progress in First Quarter 2017 Mar 15, 2017
Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio Mar 14, 2017
